| Human immunodeficiency virus I infection
Isentress vs Juluca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Isentress vs Juluca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJuluca has a higher rate of injection site reactions vs Isentress based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juluca but not Isentress, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Isentress
Juluca
At A Glance
Oral
Once or twice daily
HIV-1 integrase strand transfer inhibitor
Oral
Once daily
INSTI/NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (adults, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily or 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, treatment-experienced) 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, coadministration with rifampin) 800 mg (2 x 400 mg) twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 40 kg, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily, 400 mg twice daily, or 300 mg (3 x 100 mg) chewable tablets twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 25 kg) 400 mg film-coated tablet twice daily orally; weight-based chewable tablet dosing twice daily if unable to swallow tablet.
Human immunodeficiency virus I infection (pediatrics 3 kg to < 25 kg, >= 4 weeks of age) Weight-based dosing using chewable tablet or oral suspension twice daily orally (approximately 6 mg/kg/dose).
Human immunodeficiency virus I infection (neonates birth to 4 weeks, >= 2 kg) Weight-based oral suspension: once daily dosing (~1.5 mg/kg/dose) from birth to 1 week; twice daily dosing (~3 mg/kg/dose) from 1 to 4 weeks of age.
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Contraindications
—
- Previous hypersensitivity reaction to dolutegravir or rilpivirine
- Coadministration with dofetilide
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with systemic dexamethasone (more than a single-dose treatment)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=2%) Headache, insomnia, nausea, dizziness, fatigue.
Serious Myopathy, rhabdomyolysis, hepatitis, hepatic failure, depression including suicidal ideation and behaviors, nephrolithiasis, renal failure, hypersensitivity.
Postmarketing Thrombocytopenia, diarrhea, hepatic failure, rhabdomyolysis, cerebellar ataxia, anxiety, paranoia.
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Pharmacology
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication, preventing integration of unintegrated linear HIV-1 DNA into the host cell genome; it is eliminated primarily via UGT1A1-mediated glucuronidation and does not inhibit or induce cytochrome P450 enzymes.
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Isentress
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
Juluca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Isentress
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Juluca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Isentress
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Juluca
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IsentressView full Isentress profile
JulucaView full Juluca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.